Home » Biologics » Drug Substance » Bioconjugate Development » Partnering / Pipeline

Antibody Drug Conjugates And Bioconjugates


Catalent Biologics offers flexible options for our partners to employ SMARTag® in their bioconjugate and ADC programs, including broad research licenses, target-specific commercial licenses, co-development / product participation deals, and bundled deals including GPEx® cell line development, antibody manufacturing, and analytical services. To inquire about possible SMARTag® collaboration opportunities, including partnerships around our proprietary preclinical CD22 and HER2 ADC programs, please click here.